%D9%84%D9%8A%D9%86%D8%A7%D9%83%D9%84%D9%88%D8%AA%D9%8A%D8%AFLinaclotideLinaclotida%D9%84%DB%8C%D9%86%D8%A7%DA%A9%D9%84%D9%88%D8%AA%DB%8C%D8%AFLinaclotideLinaklotidLinaclotide%E3%83%AA%E3%83%8A%E3%82%AF%E3%83%AD%E3%83%81%E3%83%89%D0%9B%D0%B8%D0%BD%D0%B0%D0%BA%D0%BB%D0%BE%D1%82%D0%B8%D0%B4LinaklotidLinaklotidLinaclotideQ3832559
about
Chronic constipation: current treatment optionsOptimized Fmoc solid-phase synthesis of the cysteine-rich peptide linaclotide.Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors.Linaclotide - a secretagogue and antihyperalgesic agent - what next?Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.The approach to diagnosis and treatment of chronic constipation: suggestions for a general practitioner.Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation.A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipationPharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations.Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis.Current and future therapies for chronic constipation.The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide.Diagnosis and treatment of irritable bowel syndrome.Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.Linaclotide: a novel approach to the treatment of irritable bowel syndrome.Linaclotide in the management of gastrointestinal tract disorders.Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.Two randomized trials of linaclotide for chronic constipation.Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled studyClarification of trial end points presented in a recent review of linaclotide
P921
description
Linaclotide
@ru
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
name
Linaclotida
@es
Linaclotide
@it
Linaclotide
@nl
Linaclotide
@vi
Linaklotid
@hu
Linaklotid
@sh
Linaklotid
@sr
linaclotide
@en
linaclotide
@fr
Линаклотид
@ru
type
label
Linaclotida
@es
Linaclotide
@it
Linaclotide
@nl
Linaclotide
@vi
Linaklotid
@hu
Linaklotid
@sh
Linaklotid
@sr
linaclotide
@en
linaclotide
@fr
Линаклотид
@ru
altLabel
Cys cys glu tyr cys cys asn pr ...... lfide bridge: 1-6; 2-10; 5-13)
@en
L-Cysteinyl-L-cysteinyl-L-alph ...... 2->10),(5->13)-tris(disulfide)
@en
Linaclotide
@en
Linzess
@en
linzess
@ru
prefLabel
Linaclotida
@es
Linaclotide
@it
Linaclotide
@nl
Linaclotide
@vi
Linaklotid
@hu
Linaklotid
@sh
Linaklotid
@sr
linaclotide
@en
linaclotide
@fr
Линаклотид
@ru
P2175
P486
P592
P6366
P661
P662
P665
P683
P2017
C[C@H]1C(=O)N[C@H]2CSSC[C@H]3C ...... (=O)N)CC6=CC=C(C=C6)O)CCC(=O)O
P2067
P2115
N0000186137